Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

The Effect of Transforming Growth Factor-Beta Receptor Inhibition on Skin and Lung Fibrosis in Patients with Systemic Sclerosis

FY 2023-24

Summary
Systemic sclerosis (SSc) is a rare autoimmune disorder that affects mostly young and middle-aged women, resulting in significant morbidity and mortality. SSc is characterized by the thickening and tightening of the skin, connective tissue, and internal organs. The thickening and tightening of tissues is referred to as fibrosis, caused by excess collagen production and dysregulated organization of collagen in tissues. Patients living with SSc are susceptible to developing interstitial lung disease (ILD), which is defined as fibrosis of the lungs, which leads to breathing difficulties and a 10-year mortality of up to 40%. The mechanisms underlying SSc are not well understood, and currently, no treatments are available for patients with SSc and ILD that can stop or reverse fibrosis. The main cells involved in collagen production and organization within the body are fibrocytes, fibroblasts, and myofibroblasts. In SSc patients, it is understood that excess production of the growth factor, transforming growth factor-beta (TGF-?) may lead to uncontrolled upregulation of collagen production and subsequent fibrosis. The goal of this study is to use a 3-dimensional “scar-in-a-jar” collagen model to analyze differences in skin and lung fibroblasts from SSc patients with and without ILD compared to controls. We will focus on the TGF-? signaling pathway and determine if repurposing of TGF-? receptor inhibitors would be a potential therapeutic target for skin and lung fibrosis in SSc patients. This study will lead to a better understanding of the differences between skin and lung fibrosis in SSc patients and potentially develop an anti-fibrotic treatment to improve the lives and outcomes of SSc patients.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
505865
Name
Badyal Raveen K
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Effect of Transforming Growth Factor-Beta Receptor Inhibition on Skin and Lung Fibrosis in Patients with Systemic Sclerosis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Fibrotic Therapeutics; Extracellular Matrix; Fibroblasts; Interstitial Lung Disease; Lung Fibrosis; Myofibroblasts; Skin Fibrosis; Systemic Sclerosis; Transforming Growth Factor-Beta; Transforming Growth Factor-Beta Inhibitors
Abstract
Systemic sclerosis (SSc) is a rare autoimmune disorder that affects mostly young and middle-aged women, resulting in significant morbidity and mortality. SSc is characterized by the thickening and tightening of the skin, connective tissue, and internal organs. The thickening and tightening of tissues is referred to as fibrosis, caused by excess collagen production and dysregulated organization of collagen in tissues. Patients living with SSc are susceptible to developing interstitial lung disease (ILD), which is defined as fibrosis of the lungs, which leads to breathing difficulties and a 10-year mortality of up to 40%. The mechanisms underlying SSc are not well understood, and currently, no treatments are available for patients with SSc and ILD that can stop or reverse fibrosis. The main cells involved in collagen production and organization within the body are fibrocytes, fibroblasts, and myofibroblasts. In SSc patients, it is understood that excess production of the growth factor, transforming growth factor-beta (TGF-?) may lead to uncontrolled upregulation of collagen production and subsequent fibrosis. The goal of this study is to use a 3-dimensional “scar-in-a-jar” collagen model to analyze differences in skin and lung fibroblasts from SSc patients with and without ILD compared to controls. We will focus on the TGF-? signaling pathway and determine if repurposing of TGF-? receptor inhibitors would be a potential therapeutic target for skin and lung fibrosis in SSc patients. This study will lead to a better understanding of the differences between skin and lung fibrosis in SSc patients and potentially develop an anti-fibrotic treatment to improve the lives and outcomes of SSc patients.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Badyal, Raveen K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~